secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-07-03T23:59:59+00:00
Accession:  0000950170-25-093906
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics acquires early-stage life sciences company for 403k shares plus up to $89M milestones
--------------------------------------------------------------------------------

- Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).
- Earnout: up to $89M in development, clinical, and commercial milestones, payable in cash or stock at Beam's discretion.
- If milestones paid in stock, maximum issuable shares ~5.23M based on $17.01 closing price.
- Shares issued as unregistered securities under Section 4(a)(2) exemption.
- Target is an early-stage life sciences company; name not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025093906/0000950170-25-093906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025093906/beam-20250701.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-093906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer